Literature DB >> 23975180

STAT3-mediated activation of microRNA cluster 17~92 promotes proliferation and survival of ALK-positive anaplastic large cell lymphoma.

Elisa Spaccarotella1, Elisa Pellegrino, Manuela Ferracin, Cristina Ferreri, Giuditta Cuccuru, Cuiling Liu, Javeed Iqbal, Daniela Cantarella, Riccardo Taulli, Paolo Provero, Ferdinando Di Cunto, Enzo Medico, Massimo Negrini, Wing C Chan, Giorgio Inghirami, Roberto Piva.   

Abstract

Systemic anaplastic large cell lymphoma is a category of T-cell non-Hodgkin's lymphoma which can be further subdivided into two distinct entities (ALK(+) and ALK(-)) based on the presence or absence of ALK gene rearrangements. Among several pathways triggered by ALK signaling, constitutive activation of STAT3 is strictly required for ALK-mediated transformation and survival. Here we performed genome-wide microRNA profiling and identified 48 microRNA concordantly modulated by the inducible knock-down of ALK and STAT3. To evaluate the functional role of differentially expressed miRNA, we forced their expression in ALK(+) anaplastic large cell lymphoma cells, and monitored their influence after STAT3 depletion. We found that the expression of the microRNA-17~92 cluster partially rescues STAT3 knock-down by sustaining proliferation and survival of ALK(+) cells. Experiments in a xenograft mouse model indicated that forced expression of microRNA-17~92 interferes with STAT3 knock-down in vivo. High expression levels of the microRNA-17~92 cluster resulted in down-regulation of BIM and TGFβRII proteins, suggesting that their targeting might mediate resistance to STAT3 knock-down in anaplastic large cell lymphoma cells. We speculate that the microRNA-17~92 cluster is involved in lymphomagenesis of STAT3(+) ALCL and that its inhibition might represent an alternative avenue to interfere with ALK signaling in anaplastic large cell lymphomas.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23975180      PMCID: PMC4007939          DOI: 10.3324/haematol.2013.088286

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  50 in total

1.  Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells.

Authors:  Tadaaki Yamada; Shinji Takeuchi; Junya Nakade; Kenji Kita; Takayuki Nakagawa; Shigeki Nanjo; Takahiro Nakamura; Kunio Matsumoto; Manabu Soda; Hiroyuki Mano; Toshimitsu Uenaka; Seiji Yano
Journal:  Clin Cancer Res       Date:  2012-05-02       Impact factor: 12.531

2.  Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma.

Authors:  Qian Zhang; Puthryaveett N Raghunath; Liquan Xue; Miroslaw Majewski; David F Carpentieri; Niels Odum; Stephan Morris; Tomasz Skorski; Mariusz A Wasik
Journal:  J Immunol       Date:  2002-01-01       Impact factor: 5.422

3.  STAT3 mediates resistance to MEK inhibitor through microRNA miR-17.

Authors:  Bingbing Dai; Jieru Meng; Michael Peyton; Luc Girard; William G Bornmann; Lin Ji; John D Minna; Bingliang Fang; Jack A Roth
Journal:  Cancer Res       Date:  2011-03-28       Impact factor: 12.701

4.  CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.

Authors:  Mangeng Cheng; Matthew R Quail; Diane E Gingrich; Gregory R Ott; Lihui Lu; Weihua Wan; Mark S Albom; Thelma S Angeles; Lisa D Aimone; Flavio Cristofani; Rodolfo Machiorlatti; Cristina Abele; Mark A Ator; Bruce D Dorsey; Giorgio Inghirami; Bruce A Ruggeri
Journal:  Mol Cancer Ther       Date:  2011-12-27       Impact factor: 6.261

5.  Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma.

Authors:  Olaf Merkel; Frank Hamacher; Daniela Laimer; Eveline Sifft; Zlatko Trajanoski; Marcel Scheideler; Gerda Egger; Melanie R Hassler; Christiane Thallinger; Ana Schmatz; Suzanne D Turner; Richard Greil; Lukas Kenner
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-30       Impact factor: 11.205

Review 6.  MicroRNA control of signal transduction.

Authors:  Masafumi Inui; Graziano Martello; Stefano Piccolo
Journal:  Nat Rev Mol Cell Biol       Date:  2010-03-10       Impact factor: 94.444

7.  miR-17-92 cluster accelerates adipocyte differentiation by negatively regulating tumor-suppressor Rb2/p130.

Authors:  Qiang Wang; Yan Chun Li; Jinhua Wang; Juan Kong; Yuchen Qi; Richard J Quigg; Xinmin Li
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

8.  Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3-microRNA cluster 17/92 pathway.

Authors:  Matthias Brock; Michelle Trenkmann; Renate E Gay; Beat A Michel; Steffen Gay; Manuel Fischler; Silvia Ulrich; Rudolf Speich; Lars C Huber
Journal:  Circ Res       Date:  2009-04-23       Impact factor: 17.367

Review 9.  The anaplastic lymphoma kinase in the pathogenesis of cancer.

Authors:  Roberto Chiarle; Claudia Voena; Chiara Ambrogio; Roberto Piva; Giorgio Inghirami
Journal:  Nat Rev Cancer       Date:  2008-01       Impact factor: 60.716

10.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.

Authors:  S W Morris; M N Kirstein; M B Valentine; K G Dittmer; D N Shapiro; D L Saltman; A T Look
Journal:  Science       Date:  1994-03-04       Impact factor: 47.728

View more
  23 in total

1.  MiR-1224-5p acts as a tumor suppressor by targeting CREB1 in malignant gliomas.

Authors:  Jin Qian; Rui Li; Ying-Yi Wang; Yan Shi; Wen-Kang Luan; Tao Tao; Jun-Xia Zhang; Yi-Chang Xu; Yong-Ping You
Journal:  Mol Cell Biochem       Date:  2015-02-04       Impact factor: 3.396

Review 2.  Dysregulation of microRNAs and their association in the pathogenesis of T-cell lymphoma/leukemias.

Authors:  Sho Ikeda; Hiroyuki Tagawa
Journal:  Int J Hematol       Date:  2014-02-25       Impact factor: 2.490

3.  Genetics of anaplastic large cell lymphoma.

Authors:  Yu Zeng; Andrew L Feldman
Journal:  Leuk Lymphoma       Date:  2015-07-21

4.  IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma.

Authors:  Nina Prokoph; Nicola A Probst; Liam C Lee; Jack M Monahan; Jamie D Matthews; Huan-Chang Liang; Klaas Bahnsen; Ivonne A Montes-Mojarro; Elif Karaca-Atabay; Geeta G Sharma; Vikas Malik; Hugo Larose; Sorcha D Forde; Stephen P Ducray; Cosimo Lobello; Qi Wang; Shi-Lu Luan; Šárka Pospíšilová; Carlo Gambacorti-Passerini; G A Amos Burke; Shahid Pervez; Andishe Attarbaschi; Andrea Janíková; Hélène Pacquement; Judith Landman-Parker; Anne Lambilliotte; Gudrun Schleiermacher; Wolfram Klapper; Ralf Jauch; Wilhelm Woessmann; Gilles Vassal; Lukas Kenner; Olaf Merkel; Luca Mologni; Roberto Chiarle; Laurence Brugières; Birgit Geoerger; Isaia Barbieri; Suzanne D Turner
Journal:  Blood       Date:  2020-10-01       Impact factor: 22.113

Review 5.  Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine.

Authors:  Ruifang Sun; L Jeffrey Medeiros; Ken H Young
Journal:  Mod Pathol       Date:  2016-08-01       Impact factor: 7.842

Review 6.  Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution.

Authors:  Uddalak Bharadwaj; Moses M Kasembeli; Prema Robinson; David J Tweardy
Journal:  Pharmacol Rev       Date:  2020-04       Impact factor: 25.468

7.  Genome-Wide miRNA Expression Profiling of Molecular Subgroups of Peripheral T-cell Lymphoma.

Authors:  Waseem Lone; Alyssa Bouska; Sunandini Sharma; Catalina Amador; Mallick Saumyaranjan; Tyler A Herek; Tayla B Heavican; Jiayu Yu; Soon Thye Lim; Choon Kiat Ong; Graham W Slack; Kerry J Savage; Andreas Rosenwald; German Ott; James R Cook; Andrew L Feldman; Lisa M Rimsza; Timothy W McKeithan; Timothy C Greiner; Dennis D Weisenburger; Federica Melle; Giovanna Motta; Stefano Pileri; Julie M Vose; Wing C Chan; Javeed Iqbal
Journal:  Clin Cancer Res       Date:  2021-08-23       Impact factor: 13.801

8.  Pathogenetic and diagnostic significance of microRNA deregulation in peripheral T-cell lymphoma not otherwise specified.

Authors:  M A Laginestra; P P Piccaluga; F Fuligni; M Rossi; C Agostinelli; S Righi; M R Sapienza; G Motta; A Gazzola; C Mannu; E Sabattini; F Bacci; V Tabanelli; C A S Sacchetti; T Z Barrese; M Etebari; F Melle; A Clò; D Gibellini; C Tripodo; G Inghirami; C M Croce; S A Pileri
Journal:  Blood Cancer J       Date:  2014-11-07       Impact factor: 11.037

9.  Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation.

Authors:  Olaf Merkel; Frank Hamacher; Robert Griessl; Lisa Grabner; Ana-Iris Schiefer; Nicole Prutsch; Constance Baer; Gerda Egger; Michaela Schlederer; Peter William Krenn; Tanja Nicole Hartmann; Ingrid Simonitsch-Klupp; Christoph Plass; Philipp Bernhard Staber; Richard Moriggl; Suzanne D Turner; Richard Greil; Lukas Kenner
Journal:  J Pathol       Date:  2015-04-27       Impact factor: 7.996

Review 10.  The role of STAT3 in autophagy.

Authors:  Liangkun You; Zhanggui Wang; Hongsen Li; Jiawei Shou; Zhao Jing; Jiansheng Xie; Xinbing Sui; Hongming Pan; Weidong Han
Journal:  Autophagy       Date:  2015       Impact factor: 16.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.